These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2401 related items for PubMed ID: 15861314

  • 1. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 2. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
    Carmena R.
    Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B, Maes M, Zambon A.
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [Abstract] [Full Text] [Related]

  • 5. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A.
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [Abstract] [Full Text] [Related]

  • 6. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Aug; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 7. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Aug; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 8. Lipids in type 2 diabetes.
    Laakso M.
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [Abstract] [Full Text] [Related]

  • 9. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 11. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP, Mikhailidis DP, Moross T, Benson K, Gor M.
    Angiology; 2008 Feb 19; 59(1):36-46. PubMed ID: 18319220
    [Abstract] [Full Text] [Related]

  • 12. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug 19; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 13. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug 19; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 15. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ.
    Metab Syndr Relat Disord; 2009 Apr 04; 7(2):83-8. PubMed ID: 19400742
    [Abstract] [Full Text] [Related]

  • 16. Management of dyslipidemia in diabetes.
    Solano MP, Goldberg RB.
    Cardiol Rev; 2006 Apr 04; 14(3):125-35. PubMed ID: 16628021
    [Abstract] [Full Text] [Related]

  • 17. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 18. Statin therapy for the treatment of diabetic dyslipidemia.
    Haffner SM.
    Diabetes Metab Res Rev; 2003 Dec 22; 19(4):280-7. PubMed ID: 12879405
    [Abstract] [Full Text] [Related]

  • 19. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC.
    Pharmacotherapy; 1995 Dec 22; 15(3):317-37. PubMed ID: 7667166
    [Abstract] [Full Text] [Related]

  • 20. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J.
    Am J Med; 2005 Dec 22; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 121.